Federal contract award
75A50118C00019
PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $626.5M |
| Current contract value | $626.5M |
| Potential contract value / ceiling | $626.5M |
| Start date | Sep 10, 2018 |
| Current end date | Aug 30, 2029 |
| Potential end date | Aug 30, 2029 |
| Latest award activity | Aug 24, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 22 of 22 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 24, 2026 | P00021 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE CONTRACTING OFFICER REPRESENTATIVE AND ALTERNATE CONTRACTING OFFICER REPRESENTATIVE TO MATCH IPP. |
| Aug 7, 2026 | P00020 | $2.1M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 REMOVING RED DYE FROM THE TECOVIRIMAT CAPSULES FOLLOWING THE FOOD AND DRUG ADMINISTRATION (FDA) BAN OF USING RED DYE IN INGESTED DRUGS, PUBLISHED AS "FDA TO REVOKE A |
| Jun 3, 2025 | P00019 | $13.2M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 FOR PEDIATRIC FORMULATION DEVELOPMENT, UPDATE ARTICLE B.2 BASE PERIOD, ARTICLE G.2. CONTRACTING OFFICER?S REPRESENTATIVE, AND SECTION J - LIST OF ATTACHMENTS, ATTACHMENT |
| Apr 7, 2025 | P00018 | $14.3M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 FOR THE TECHNICAL TRANSFER OF INTRAVENOUS TECOVIRIMAT TO A NEW CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO), UPDATE SECTION B - SUPPLIES OR SERVICES AND PRI |
| Mar 24, 2025 | P00017 | $25.6M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION CLIN 0023, 0025, AND 0027 AND UPDATE ARTICLE I.1 FEDERAL ACQUISITION REGULATIONS (FAR) (48 CFR CHAPTER 1) CLAUSES IN ACCORDANCE WITH CLASS DEVIATION (CD) NO. 2025-01 FROM THE FEDER |
| Jul 16, 2024 | P00016 | $112.6M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION CLIN 0012 AND REVISE SECTION G CONTRACT ADMINISTRATION, ARTICLE G.1 CONTRACTING OFFICER FROM JONATHAN GONZALEZ TO AUDREY GLOVER. |
| Feb 9, 2024 | P00015 | $0 | ADMINISTRATIVE CORRECTIONS |
| Oct 18, 2023 | P00014 | $0 | ADMINISTRATIVE CORRECTIONS |
| Jul 27, 2023 | P00013 | $138.2M | EXERCISE OPTION CLIN 0011, 0018, 0020, 0022 |
| Aug 4, 2022 | P00012 | $29.2M | EXERCISE CLIN 0008, 0013, 0015, AND 0017 |
| Jul 26, 2022 | P00011 | $0 | ADMIN CHANGE TO CORRECT ERROR |
| Mar 29, 2022 | P00010 | $0 | ADD IPP CLAUSE HHSAR CLAUSE 352.232-71 - ELECTRONIC SUBMISSION OF PAYMENT REQUESTS |
| Jan 27, 2022 | P00009 | $0 | ADMIN NO-COST MOD 9 EXTENDS CX LINE ITEMS 7 & 8 DELIVERY DATE TO 3/31/2022 AND CLARIFIES CONTRACT'S FULL TERM END DATE OF 9/9/2028. |
| Nov 1, 2021 | P00008 | $0 | EXECUTIVE ORDER 14042 - FAR DEVIATION CLAUSE 52.223-99 TO PROVIDE ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS. |
| Sep 7, 2021 | P00007 | $112.6M | EXERCISE OF OPTION CLIN 0010 FOR ADDITIONAL PROCUREMENT OF NONPARENTERAL (ORAL)FORMULATED ANTIVIRAL AS FDP AND DELIVERY TO THE SNS |
| Apr 26, 2021 | P00006 | $15.4K | SUPPLEMENTAL FUNDING FOR CLIN 0006, DELIVERY OF PV LOT TO SNS AND DOD. CHANGE IN COR & CO. |
| Apr 23, 2020 | P00005 | $101.3M | EXERCISE OF FIRM FIXED PRICE CLINS 0009 B, C, AND D FOR FINAL PROCESSING OF 362,365 TREATMENT COURSES OF TPOXX FOR BARDA AND SNS. |
| Jan 15, 2020 | P00004 | $0 | MOD FOR SUPPLEMENTAL FUNDING FOR CLIN 7 CHANGES TO COMPLETE FDA REQUIRED PH IV POST-MARKETING STUDY OPTION. CHANGE IN CLIN 0003&0007 DESCRIPTION AND RELATED SOW. CHANGE IN CO. |
| Sep 5, 2019 | P00003 | $2.4M | MOD FOR SUPPLEMENTAL FUNDING FOR CLIN 7 CHANGES TO COMPLETE FDA REQUIRED PH IV POST-MARKETING STUDY OPTION. CHANGE IN CLIN 0003&0007 DESCRIPTION AND RELATED SOW. CHANGE IN CO. |
| May 20, 2019 | P00002 | $11.3M | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF THE PURPOSE OF THIS MODIFICATION IS TO (1) EXERCISE OPTION CLIN0009A IN THE AMOUNT OF $11,255,170.00, (2) MODIFY ARTICLE G.2. TO CHANGE THE CONTRACTING OFFICER'S REPRESENTATIVE AS FOLLOWS; (3) REVISE ARTICLE B.3. TO BREAKOUT CLIN0009 INTO FOUR SUBPARTS (0009A, 0009B, 0009C, 0009D) AS FOLLOWS. ALL OTHER TERMS AND CONDITIONS IN THE CONTRACT REMAIN UNCHANGED. |
| Feb 21, 2019 | P00001 | $12.2M | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION CLIN0007 IN THE AMOUNT OF $12,186,975.00 AND CHANGE THE COR INFORMATION LISTED IN ARTICLE G.2 AS FOLLOWS. |
| Sep 10, 2018 | 0 | $51.6M | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF |
Estimated positioning window
Aug 30, 2028 – Feb 28, 2029
Recompete signal: . Rule-based research score; positioning dates are estimates.
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2029-08-30 (1033 days from calculation)
- +15 points
- 121 historical awards in this buyer and category group
- +15 points
- 22 recorded award transactions
- +10 points
- Latest award action: 2026-08-24
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.